BeiGene wins Scrip Award
The pharmaceutical company BeiGene has won a Scrip Award that recognizes contributions across the pharma sector to improving healthcare. BeiGene’s European headquarters is located in Basel.
The winners of the Scrip Awards 2019 (img: firstname.lastname@example.org)
The 15th edition of the Scrip Awards this year honored companies in pharma, biotech and associated sectors that are making important contributions to improving healthcare. The Chinese company BeiGene won the award in the category Masters Speciality Pharma’s Best Company in an Emerging Market. The globally active company from Beijing opened its European headquarters in Basel in 2018, with the settlement facilitated by BaselArea.swiss.
BeiGene specializes in the development of cancer therapies. Seeking to secure a leading role worldwide in the discovery, development and commercialization of drugs for targeted cancer treatment and the field of immuno-oncology, the company looks to distinguish itself with innovative approaches. It has now succeeded in this at the Scrip Awards, where it beat five other companies nominated in the category Masters Speciality Pharma’s Best Company in an Emerging Market.
Awards were given in 17 categories. Novartis and AveXis won IQVIA’s Clinical Advance of the Year Award, which recognizes a clinical Phase III study on Zoglensma – a gene therapy for the degenerative nervous system disease amyotrophic lateral sclerosis (ALS). The American company AveXis was acquired last year by the Basel pharmaceutical company Novartis.
Share this article
You might also be interested in
Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.Read More
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More